semaglutide loss of exclusivity (Ozempic) Market: Navigating The Patent Cliff And Strategic Implications Ozempic's patent problem: how Novo

A new survey report from the International Foundation of Employee Benefit Plans reveals U.S

Semaglutide is already getting cheaper in some markets where the Ozempic patent has expired, including India, China and Canada

In this double-blind, placebo-controlled phase 2, trial, 507 adults with obesity (body mass index 30 kg m 2 or 27 kg m 2 with at least one obesity-associated complication (excluding diabetes) were randomized to nine groups (1:1:1:1:1:1:1:1:1 ratio) to receive treatment for 48 weeks: placebo, bimagrumab (10 mg kg 1 or 30 mg kg 1 intravenously every 12 weeks), semaglutide (1.0 mg or 2.4 mg subcutaneously once a week) and combinations thereof

We expect our suppliers to uphold the same standards we set for ourselves by operating with integrity and adhering to relevant laws, regulations and the principles outlined in the Ascendis Pharma Code of Business Conduct & Ethics